Impact of Antenatal Corticosteroid Therapy on Postnatal Surfactant Use in Preterm Infants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

145 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-20

Study Completion Date

2022-07-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

No study has shown that two doses of corticosteroids are more effective than a single dose in lung maturation and prevention of hyaline membrane disease (HMD) The aim of this study is to assess the impact of the number of doses on the severity of HMD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antenatal Steroids Effect on Mortality and Respiratory Outcomes in Preterm Infants

NCT04214795

Morbidity;Newborn

UNKNOWN

Evaluation of Serial Lung Ultrasound Data After Surfactant Treatments Applied With Different Methods in Preterm Babies

NCT06880016

Newborn Complication Respiratory Distress Syndrome, Newborn

RECRUITING NA

Antenatal Dexamethasone for Late Preterm Deliveries

NCT05841121

Respiratory Distress of Newborn Preterm Birth

RECRUITING PHASE1

Prevention of Neonatal Respiratory Distress Syndrome With Antenatal Steroid Administration

NCT00000563

Lung Diseases Respiratory Distress Syndrome

COMPLETED PHASE3

Surfactant Replacement Guided by Early Lung Ultrasound Score in Preterm Newborns With Respiratory Distress Syndrome

NCT04775459

Preterm Birth

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Respiratory distress syndrome (RDS), formerly known as hyaline membrane disease, is a common problem in preterm infants. This disorder is caused primarily by deficiency of pulmonary surfactant in an immature lung. RDS is a major cause of morbidity and mortality in preterm infants.

Surfactant therapy has been shown to significantly reduce neonatal and infant mortality. Corticosteroids are given antenatal, and then surfactant is given, along with corticosteroids, postnatal.

A single course of corticosteroids is recommended for pregnant women between 24 weeks and 34 weeks of gestation who are at risk of preterm delivery within 7 days, including those with ruptured membranes and multiple pregnancies.

Betamethasone is recommended as the steroid of choice, to be administered in two doses of 12 mg given intramuscularly 24 hours apart.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyaline Membrane Disease (HMD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Impact of antenatal corticosteroid therapy on surfactants use postnatal

Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal

Impact of antenatal corticosteroid therapy on surfactants use postnatal

Intervention Type OTHER

Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Impact of antenatal corticosteroid therapy on surfactants use postnatal

Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Preterm infants ≤ 37 SA
* Hospitalized in the neonatal intensive care unit between January 2018 and December 2019
* Having received at least one dose of corticosteroids antenatal